Bio-Rad Laboratories had a tough Q1 but is optimistic about future growth potential.

From Yahoo Finance: 2025-04-21 08:08:00

Longleaf Partners Fund, managed by Southeastern Asset Management, reported a -5.14% return in Q1 2025, compared to S&P 500’s -4.27%. The fund saw volatile stock performance but remains confident in future returns. Bio-Rad Laboratories, Inc. (NYSE:BIO) lost 15.24% over 52 weeks, closing at $238.18 with a $6.691 billion market cap on April 17, 2025.

Bio-Rad Laboratories, Inc. (NYSE:BIO) detracted in Q1 2025 but remains a stable business with growth potential. The company faced challenges with government funding cuts and disappointing results. Despite this, its outlook is optimistic, with strong balance sheet, hidden asset in Sartorius stake, and history of smart capital allocation.

Bio-Rad Laboratories, Inc. (NYSE:BIO) is not among the 30 Most Popular Stocks Among Hedge Funds, with 42 portfolios holding it in Q4 2024. Hedge funds see potential in Bio-Rad Laboratories, Inc. (NYSE:BIO) but believe AI stocks offer greater returns in a shorter timeframe. Explore AI stock picks for promising investments.



Read more at Yahoo Finance: Should You be Optimistic on Bio-Rad Laboratories’s (BIO) Outlook?